ANI Pharmaceuticals logo

ANI Pharmaceuticals

ANIP | NASDAQ
Chart Builder DCF Calculator
$70.89
-$0.55 (-0.77%)
At close: Nov 16, 2026, 4:00 PM ET
$70.84
-$0.05 (-0.07%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.77%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
80.2
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #21/1021 (Top 2%)

Key Statistics

Market Data

Market Cap $1.61B
1D Range
69.72 71.96
52W Range
67.41 86.03

Valuation (TTM)

PE 14.15
PB 2.53
EV/EBITDA 5.44

Valuation (NTM)

Forward PE 7.54
Forward PEG 0.54
Price Target $97.00
Loading financial charts...

Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides i...

Sector Healthcare
Employees 970
IPO Date May 5, 2000
Fiscal Year January - December

Latest News

ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript

10 days ago · seekingalpha.com

ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript
ANI Pharmaceuticals Q3 Earnings Call Highlights

12 days ago · marketbeat.com

ANI Pharmaceuticals Q3 Earnings Call Highlights
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say

12 days ago · zacks.com

ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

12 days ago · zacks.com

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

12 days ago · globenewswire.com

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

12 days ago · globenewswire.com

REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

12 days ago · globenewswire.com

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

14 days ago · globenewswire.com

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

25 days ago · globenewswire.com

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

29 days ago · globenewswire.com

ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

Earnings

Latest Earnings
Nov 5, 2026
EPS
$2.7
Beat +23.85%
REV
$290.78M
Beat +3.63%
Next Earnings
Feb 26, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Hold
Price Target
$97.00
Upside
+36.83%
Buy (1)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.